secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2023-10-02T23:59:59+00:00
Accession:  0000950170-23-050856
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics notified of non-compliance with Nasdaq $1.00 bid price rule; 180-day cure period to March 2024
--------------------------------------------------------------------------------

- Received deficiency notice on Sep 26, 2023 after 30 consecutive business days of closing bid price below $1.00.
- Must regain compliance by March 25, 2024 by achieving $1.00 close for at least 10 consecutive business days.
- May be eligible for additional 180-day cure period if meeting other Nasdaq listing standards and providing written intent to cure.
- Company will consider all options, including a potential reverse share split, to address the deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023050856/0000950170-23-050856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017023050856/itrm-20230926.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-050856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer